VEGFA and type 1 diabetes mellitus: In conclusion, our work provides new insight into the mechanism of β-cell recovery after injury mediated by hBMSC therapy and demonstrates the possible clinical benefit of hBMSCs expressing VEGF for the treatment of insulin-dependent diabetes.